Brief: Neurovive Decides On A Rights Issue For Continued Drug Development

Abliva AB

15/02/2018 07:35

Feb 15 (Reuters) - NEUROVIVE PHARMACEUTICAL AB  NVP.ST : 
    * NEUROVIVE DECIDES ON A RIGHTS ISSUE FOR CONTINUED DRUG 
DEVELOPMENT 
    * TO ISSUE SHARES AND WARRANTS WITH PREFERENTIAL RIGHTS FOR 
EXISTING SHAREHOLDERS ("RIGHTS ISSUE") 
    * UPON FULL SUBSCRIPTION TO RIGHTS ISSUE, CO WILL RECEIVE 
ABOUT 
MSEK 78.5 BEFORE ISSUANCE COSTS. 
    * IN FULL EXERCISE OF WARRANTS ISSUED IN RIGHTS ISSUE, CO 
WILL 
RECEIVE AN ADDITIONAL MSEK 37.3 BEFORE ISSUANCE COSTS. 
    * SUBSCRIPTION PRICE IS SEK 8 PER UNIT, CORRESPONDING TO 
SEK 2 
PER SHARE. 
    * SUBSCRIPTION PERIOD RUNS FROM 10 APRIL - 24 APRIL 2018. 
 
Source text for Eikon:  ID:nWkrc9Twy5  
Further company coverage:  NVP.ST  
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))